Oncopeptides AB (publ) announced that Sofia Heigis who will move from the CCO role to take on the CEO role.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.16 SEK | -8.14% | -13.07% | -58.75% |
May. 30 | Oncopeptides Issues Warrants Under Loan Deal with European Investment Bank | MT |
May. 30 | Transcript : Oncopeptides AB, Q1 2024 Earnings Call, May 30, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.75% | 64.54M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ONCO Stock
- News Oncopeptides AB
- Oncopeptides AB Announces Sofia Heigis to Move from the CCO Role to CEO Role